21/10/2022 (Agence Europe) – The European Commission authorised, on Thursday 20 October, the bivalent messenger RNA vaccine developed by the pharmaceutical company Moderna and adapted to combat not only the original SARS-CoV-2 strain but also two of its sub-variants of concern: BA.4 and BA.5 (Omicron). The Commission’s decision is based on the scientific assessment of the European Medicines Agency (EMA), which issued a favourable recommendation the same day (see EUROPE B13047A22). The...